GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Gross-Profit-to-Asset %

Nectar Lifesciences (LUX:NECLF) Gross-Profit-to-Asset % : 24.08% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nectar Lifesciences's annualized Gross Profit for the quarter that ended in Mar. 2024 was $63.6 Mil. Nectar Lifesciences's average Total Assets over the quarter that ended in Mar. 2024 was $263.9 Mil. Therefore, Nectar Lifesciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 24.08%.


Nectar Lifesciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Nectar Lifesciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Gross-Profit-to-Asset % Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.33 10.39 12.24 15.28 21.90

Nectar Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.77 21.01 20.57 23.25 24.08

Competitive Comparison of Nectar Lifesciences's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Gross-Profit-to-Asset % falls into.



Nectar Lifesciences Gross-Profit-to-Asset % Calculation

Nectar Lifesciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=58.039/( (266.112+263.915)/ 2 )
=58.039/265.0135
=21.90 %

Nectar Lifesciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=63.56/( (0+263.915)/ 1 )
=63.56/263.915
=24.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Nectar Lifesciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences (LUX:NECLF) Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines